EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension

Gusty Rizky Teguh Ryanto iD, Ahmad Musthafa, Tetsuya Hara, Noriaki Emoto iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24043332 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Gusty Rizky Teguh Ryanto und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe 658-8558, Japan. Hauptthemen laut MEDLINE: Inhibins, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advances in technology and biomedical knowledge have led to the effective diagnosis and treatment of an increasing number of rare diseases. Pulmonary arterial hypertension (PAH) is a rare disorder of the pulmonary vasculature that is associated with high mortality and morbidity rates. Although significant progress has been made in understanding PAH and its diagnosis and treatment, numerous unanswered questions remain regarding pulmonary vascular remodeling, a major factor contributing to the increase in pulmonary arterial pressure. Here, we discuss the role of activins and inhibins, both of which belong to the TGF-β superfamily, in PAH development. We examine how these relate to signaling pathways implicated in PAH pathogenesis. Furthermore, we discuss how activin/inhibin-targeting drugs, particularly sotatercep, affect pathophysiology, as these target the afore-mentioned specific pathway. We highlight activin/inhibin signaling as a critical mediator of PAH development that is to be targeted for therapeutic gain, potentially improving patient outcomes in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InhibinsPulmonary Arterial HypertensionHumansActivinsTransforming Growth Factor beta

Stichwörter der Autor:innen

activinpulmonary arterial hypertensionvascular remodeling

Substanzen

InhibinsActivinsTransforming Growth Factor beta

Autor:innen und Institutionen

  • Laboratory of Clinical Pharmaceutical Science, Kobe Pharmaceutical University, Kobe 658-8558, Japan.
  • Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan.

ORCID-Profile: Gusty Rizky Teguh Ryanto, Noriaki Emoto

Zitieren

APA

Ryanto, G. R. T., Musthafa, A., Hara, T., & Emoto, N. (2023). Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24043332

Vancouver

Ryanto GRT, Musthafa A, Hara T, Emoto N. Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24043332

BibTeX
@article{Ryanto2023,
  author = {Ryanto, Gusty Rizky Teguh and Musthafa, Ahmad and Hara, Tetsuya and Emoto, Noriaki},
  title = {Inactivating the Uninhibited: The Tale of Activins and Inhibins in Pulmonary Arterial Hypertension},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24043332}
}
Kostenlos starten →